San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of two (2) new Varicella Zoster Virus (VZV) antigens to its broad offering of products for in-vitro diagnostic (IVD) manufacturing and research applications. Both the standard VZV antigen, along with the VZV glycoprotein antigen, have been expressly designed for use as integral components within solid phase enzyme immunoassay test procedures. As such, the availability of these two antigens will benefit the needs of biopharmaceutical, clinical, drug-discovery, and life science researchers, as well as manufacturers of IVD test kits.
VZV is one of eight herpes viruses known to infect humans. VZV infections are species-specific to humans and causes chickenpox (varicella), a disease most commonly affecting children, teens, and young adults, as well as herpes zoster in older adults. VZV is known by many names, including chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3).
Both VZV antigens exhibit exceptional purity levels as a result of chromatography techniques. Plus, they demonstrate exceptional lot-to-lot consistencies, while displaying the highest degrees of activity and specificity. They all feature an outstanding shelf life stability claim of 10 years from the date of manufacture and are offered in a standard sized 1.0mg filled vial, with larger, bulk configurations also being available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: firstname.lastname@example.org. Please visit our website at www.immunologicals.com.